![Page 1: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/1.jpg)
+
Glomerulopathies: clinical syndromesNovember 6, 2015
![Page 2: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/2.jpg)
+Which patient is sicker?
Se-creatinine 561 microm/l Previous measurement 576
microm/l Next measurement 542
microm/l Daily urine output: 1.4 l Se-potassium: 3.5 mmol/l pH: 7.28
Se-creatinine: 303 microm/l Previous measurement 576
microm/l Next measurement 581
microm/l Daily urine output: 150 ml Se-potassium: 6.3 mmol/l pH: 7.29
![Page 3: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/3.jpg)
+Which patient is sicker?
Se-creatinine 561 microm/l Previous measurement 576
microm/l Next measurement 542
microm/l Daily urine output: 1.4 l Se-potassium: 3.5 mmol/l pH: 7.28
Se-creatinine: 303 microm/l Previous measurement 176
microm/l Next measurement 581
microm/l Daily urine output: 150 ml Se-potassium: 6.3 mmol/l pH: 7.29
![Page 4: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/4.jpg)
+Which patient is sicker?
Se-creatinine 561 microm/l Previous measurement 576
microm/l Next measurement 542
microm/l Daily urine output: 1.4 l Se-potassium: 3.5 mmol/l pH: 7.28
Se-creatinine: 303 microm/l Previous measurement 176
microm/l Next measurement 581
microm/l Daily urine output: 150 ml Se-potassium: 6.3 mmol/l pH: 7.29
![Page 5: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/5.jpg)
+Which patient is sicker?
Se-creatinine 561 microm/l Previous measurement 576
microm/l Next measurement 542
microm/l Daily urine output: 1.4 l Se-potassium: 3.5 mmol/l pH: 7.28
Se-creatinine: 303 microm/l Previous measurement 176
microm/l Next measurement 581
microm/l Daily urine output: 150 ml Se-potassium: 6.3 mmol/l pH: 7.29
![Page 6: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/6.jpg)
+General aspects for disease categories Kidney function Time course Urine volume Urine findings Histology Complaints Symptomes
“Too many secrets”
![Page 7: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/7.jpg)
+Kidney function
Simplest: eGFR CKD-EPI (age, gender) MDRD (age) Cockroft-Gault (age, gender, body weight)
24 h urine: creatinine clearance Isotope scintigraphy Cystatin C Inulin
![Page 8: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/8.jpg)
+Time: course of the disease
Acute onset: days to hours Subacute: week-month Chronic: years
![Page 9: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/9.jpg)
+Urine output definition
Oliguria <500 ml/day<17-21 ml/h<0.24-0.3 ml/kg/h<0.5 ml/kg/h
Anuria <100 ml/day
Polyuria >2.5-2 l/day
![Page 10: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/10.jpg)
RIFLE Criteria
![Page 11: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/11.jpg)
+Urinanalysis findings
Nephrotic Nephritic*Protein over 3.5 g/24 h Protein less than 1.5 g/24 h
Dysmorphic red blood cells = Acanthocytes
Fatty casts Red cell castsWhite blood cells
* If glomeruli affected diffusely heavy or nephrotic range proteinuria, hypalbuminaemia, edema, hypertension and renal insufficiency can also be observed.
![Page 12: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/12.jpg)
+Proteinuria
Overflow: abnormal serum protein components Glomerular: abnormal glomerular structure
Selective: minimal-change nephrotic syndrome Non-selective: glomerulonephritis, diabetic nephropathy
Tubular: interstitial nephritis Hemodynamic: heart failure
![Page 13: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/13.jpg)
+Indication for kidney biopsy
Diagnostic in cases with proteinuria greater than 2 g/day, hematuria, RBC casts
Diagnostic in cases with renal failure and kidney size is normal and other approaches are non-conclusive
Follow-up in diseases such as SLE, pulmonary-renal syndromes, paraproteinaemias
![Page 14: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/14.jpg)
+Approach to kidney patients
Serum chemistry: Na, K, CN, Kreat, Mg, Ca, Phosph, uric acid, albumin GFR Urine dipstick 24-hour urine sample ESR, ANA, ANCA, anti-GBM, C3, cryoglobulins Hepatitis B, C, AST Serum and urine protein ELFO Imaging Renal biopsy
![Page 15: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/15.jpg)
+Classification of glomerulopathies Nephrotic syndrome – massive proteinuria (>3.5 g/day),
hypoalbuminaemia, oedema, lipiduria and hyperlipidaemia.
Acute glomerulonephritis (acute nephritic syndrome) – abrupt onset of glomerular haematuria (RBC casts or dysmorphic RBC), non-nephrotic range proteinuria, oedema, hypertension and transient renal impairment.
Rapidly progressive glomerulonephritis – features of acute nephritis, focal necrosis with or without crescents and rapidly progressive renal failure over weeks.
Asymptomatic haematuria, proteinuria or both.
Chronic glomerulonephritis – Persistent proteinuria with or without haematuria and slowly progressive impairment of renal function
![Page 16: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/16.jpg)
+Thesaurus: Pathological terms Focal: some, but not all, glomeruli show the lesion
Diffuse (global): most of the glomeruli (>75%) contain the lesion
Segmental: only a part of the glomerulus is affected (most focal lesions are also segmental, e.g. focal segmental glomerulosclerosis)
Proliferative: an increase in cell numbers due to hyperplasia of one or more of the resident glomerular cells with or without inflammation
Membrane alterations: capillary wall thickening due to deposition of immune deposits or alterations in basement membrane
Crescent formation: epithelial cell proliferation with mononuclear cell infiltration in Bowman’s space.
![Page 17: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/17.jpg)
Dr. Járay Jenő, dr. Hidvégi Márta MANET Nagygyűlés, 2002
![Page 18: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/18.jpg)
+Playground: only two compartments
![Page 19: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/19.jpg)
+Sites of kidney injury and renal function
![Page 20: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/20.jpg)
+Features of glomerulopathies (GN)
primarily an immunologically mediated injury to glomeruli, (renal interstitial damage is a regular accompaniment)
the kidneys are involved symmetrically secondary mechanisms of glomerular injury come into
play following an initial immune insult (such as fibrin deposition, platelet aggregation, neutrophil infiltration)
renal lesions may be part of a generalized disease (e.g. systemic lupus erythematosus, SLE).
![Page 21: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/21.jpg)
+Cells involved in GNs
![Page 22: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/22.jpg)
+Link among syndrome and treatment
Membranous ProliferativeClinical syndrome Nephrotic-sy Nephritic-sy
Treatment Steroid Immunosuppression
![Page 23: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/23.jpg)
+Nephrotic syndrome
Heavy proteinuria Hypalbuminaemia Hypercholersterolaemia Edema Risk of thrombotic events
![Page 24: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/24.jpg)
+Minimal change nephritis
Mainly childhood or young adults Nephrotic Secunder forms: lymphomas, Hodgkin’s disease EM: foot process fusion Steroids ESRD not typical
![Page 25: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/25.jpg)
+Focal segmental glomerulosclerosis Mainly adulthood Nephrotic Secunder forms: AIDS, SLE Remissions and relapses Steroids ESRD frequent (30-60%)
![Page 26: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/26.jpg)
+Membranosus nephropathy
Any age Isolated proteinuria – nephrosis Secunder form: malignant diseases, SLE Prognostic factors determine outcome Remissions and relapses Steroid + cytotoxic treatment ESRD frequent (30-50%)
![Page 27: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/27.jpg)
+Poor prognostic factors in MN
Age over 50 yrs Male gender Hypertension Reduced GFR Proteinuria greater than 10 g/day Interstitial fibrosis in Histology
![Page 28: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/28.jpg)
![Page 29: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/29.jpg)
+Acute nephritic syndrome
Haematuria (macroscopic or microscopic) – red-cell casts are typically seen on urine microscopy
Proteinuria Hypertension Oedema (periorbital, leg or sacral) Temporarily oliguria and uraemia.
![Page 30: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/30.jpg)
+Post-streptococcal GN
Kids Acute nephritic sy Streptococcal infection: throat, pyoderma AST increased Subepithelial hump deposits No specific therapy, anti-streptococcal antibiotics ESRD not likely
![Page 31: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/31.jpg)
+Membranoproliferative GN
Young adults Various forms: Nephroso-nephritic, simple proteinuria,
acute nephritis Secunder forms: Hepatitis B, C, SLE C3 level low Steroid+ cytotoxic drugs ESRD likely 30%
![Page 32: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/32.jpg)
![Page 33: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/33.jpg)
+Rapidly progressive glomerulonephritis 50% decline in kidney function in 3 month Hematuria and casts Type I: anti GBM disease (type II hypersensitivity) Type II: immuncomplex disease (type III
hypersensitivity) eg: SLE, Schonlein-Henoch purpura, SLE
Type III: ANCA positive vasculitis, pauci-immune GN
![Page 34: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/34.jpg)
+Anti-GBM glomerulonephritis
Above 50 yrs If lungs are involved Goodpasture’s sy Rapidly progressive GN C3 normal ANCA positivity Plasmapheresis ESRD frequent
![Page 35: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/35.jpg)
+ANCA-positive vasculitides
Wegener’s granulomatosis,
microscopic polyangiitis
Churg–Strauss syndrome
![Page 36: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/36.jpg)
+ANCA positive (pauci-immun) GN Focal ( ≥50% normal glomeruli that are not affected by
the disease process)
Crescentic ( ≥50% of glomeruli with cellular crescents)
Mixed (a heterogeneous glomerular phenotype wherein no glomerular feature predominates)
Sclerotic (≥50% of glomeruli with global sclerosis).
![Page 37: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/37.jpg)
![Page 38: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/38.jpg)
+IgA nephropathy
Adult, male Mesangial IgA deposits Asymptomatic hematuria, but 10% nephrotic Secondary forms: hepatic cirrhosis, gluten sensitive
enteropathy, dermatitis herpetiformis No optimal therapy: steroid, fish oil, ACEi ESRD possible in 20-30%
![Page 39: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/39.jpg)
+Lupus nephritis Class I – Minimal mesangial lupus nephritis (LN), with immune deposits but
normal on light microscopy. Asymptomatic. Class II – Mesangial proliferative LN with mesangial hypercellularity and matrix
expansion. Clinically, mild renal disease. Class III – Focal LN (involving <50% of glomeruli) with subdivisions for active or
chronic lesions. Subepithelial deposits seen. Clinically have haematuria and proteinuria; 10–20% of all LN.
Class IV – Diffuse LN (involving >50% of glomeruli) classified by the presence of segmental and global lesions as well as active and chronic lesions. Subendothelial deposits are present. Clinically, there is progression to the nephrotic syndrome, hypertension and renal insufficiency. Most common and most severe form of LN.
Class V – Membranous LN affects 10–20% of patients. Can occur in combination with III or IV. Good prognosis.
Class VI – Advanced sclerosing LN (≥90% globally sclerosed glomeruli without residual activity). This represents the advanced stages of the above, as well as healing. Immunosuppressive therapy is unlikely to help as it is ‘inactive’. Progressive CKD.
![Page 40: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/40.jpg)
+Therapeutical approaches
Volume control: Appropriate circulating volume, no overload either
RR control: hypertension, hypotension should be avoided
Proteinuria: ACEi, ARB: maximal tolerable dose Hyperlipidaemia: statins Dietary: sufficient energy, protein restriction
![Page 41: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/41.jpg)
+Practical map Nephrotic syndrome
MCD FSGS MN
Rapidly progressive GN Anti-GBM GN Immuncomplex D ANCA-pos pauci immun
GN
Acute nephritic syndrome Poststreptococcal GN MPGN
Isolated hematuria IgA
Chronic kidney diease
![Page 42: + Glomerulopathies: clinical syndromes November 6, 2015](https://reader036.vdocuments.site/reader036/viewer/2022062401/5a4d1aeb7f8b9ab05997a84d/html5/thumbnails/42.jpg)
+Bigger resolution for advanced adverturersAGE Nephrotic Mild nephritic Severe nephritic<15 MCD, FSGS,
MesaProlGPostinfect, IgAN, HSP
Postinfect, MembranoprolGN
15-40 FSGS, MCD, MN, DN
IgAN, thin basal membrane D, LN, MesaProlG
Postinfect, LN, RPGN, IgAN, MembranoprolGN
>40 FSGS, MN, DN, MCD, IgAN
IgAN RPGN, vasculitis, IgAN
MCD: minimal change, FSGS: focal segmental glomerulosclerosis, MesaProl: mesangioproliferative GN, MN: Membranosus nephropathy, DN: Diabetic nephropathy, IgAN: IgA nephropathy, Postinfect: postinfectious nephropathy, HSP: Henoch-Schonlein purpura,